Changes in adrenal neuropeptides content [peptide 7B2, neuropeptide Y (NPY) and vasoactive intestinal polypeptide (VIP)] induced by pharmacological and hormonal manipulations.

Tsuchiya T, Suzuki Y, Suzuki H, Ohtake R, Shimoda SI

Journal of endocrinological investigation1 May 1990Cited by 7 (Europe PMC)

PMID2380503DOI10.1007/bf03350684PepBankPUB-02380503

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Natural levels measured6

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

01AnimalEndogenous levelAnimal study (in vivo)Other
In Wistar rats, chlorpheniramine maleate treatment decreased the body's own adrenal VIP content.
In plain wordsIn rats, an antihistamine lowered the body's own VIP content in the adrenal gland.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseAdrenal VIP content after chlorpheniramine
Study
ratn: not reported in source
Wistar rats, adrenal gland content by radioimmunoassay
Outcome group
Endogenous peptide levels · Endocrine and hormones
Source sentences
Summary
RES and RANT treatments caused significant 7B2 reduction (p less than 0.01) and adrenal NPY was significantly decreased by RES (p less than 0.05), while CPhM induced a VIP decreased (p less than 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
In order to elucidate the neural and humoral regulation of adrenal 7B2, NPY and VIP content, Wister rats were treated with reserpine (RES), ranitidine (RANT) or chlorpheniramine maleate (CPhM) for 7-10 days.
Summary · context
7B2, NPY and VIP contents were measured by specific radioimmunoassays.
This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-0238050301
02AnimalEndogenous levelAnimal study (in vivo)Other
In rats, orchiectomy did not affect the adrenal content of VIP.
In plain wordsIn rats, removal of the testes did not change the body's own VIP content in the adrenal gland.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeAdrenal VIP content after orchiectomy
Study
ratn: not reported in source
Wistar rats, adrenal gland content by radioimmunoassay
Outcome group
Endogenous peptide levels · Endocrine and hormones
Source sentences
Summary
Orchiectomy did not affect the peptides concentrations, though MSG treatment did cause a reverse change in VIP and NPY.
2 context sentences(design, population, supporting numbers)
Summary · context
Orchiectomy or neonatal monosodium glutamate (MSG) treatment was also done.
Summary · context
7B2, NPY and VIP contents were measured by specific radioimmunoassays.
This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-0238050302
03AnimalEndogenous levelAnimal study (in vivo)Other
In rats, neonatal monosodium glutamate treatment changed adrenal VIP and NPY content; the abstract calls it a reverse change and does not state the direction for VIP.
In plain wordsIn rats, early-life glutamate treatment changed the body's own VIP content in the adrenal gland; the direction of the change is not stated.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Direction not reportedAdrenal VIP content after neonatal monosodium glutamate
Study
ratn: not reported in source
Wistar rats, adrenal gland content by radioimmunoassay
Outcome group
Endogenous peptide levels · Endocrine and hormones
Source sentences
Summary
though MSG treatment did cause a reverse change in VIP and NPY.
2 context sentences(design, population, supporting numbers)
Summary · context
Orchiectomy or neonatal monosodium glutamate (MSG) treatment was also done.
Summary · context
7B2, NPY and VIP contents were measured by specific radioimmunoassays.
This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-0238050303
04AnimalEndogenous levelAnimal study (in vivo)Other
In rats, thyroxine administration did not significantly change adrenal VIP content.
In plain wordsIn rats, thyroid hormone treatment did not change the body's own VIP content in the adrenal gland.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeAdrenal VIP content after thyroxine
Study
ratn: not reported in source
Wistar rats, adrenal gland content by radioimmunoassay
Outcome group
Endogenous peptide levels · Endocrine and hormones
Source sentences
Summary
Although T4 administration did not cause any significant change
2 context sentences(design, population, supporting numbers)
Summary · context
The thyroid hormone excess and deficient states were experimentally produced with thyroxine (T4) treatment for 2 weeks, methylmercaptoimidazole (MMI) for 4 weeks, or a thyroidectomized state (Tx) for 4 weeks.
Summary · context
7B2, NPY and VIP contents were measured by specific radioimmunoassays.
This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-0238050304
05AnimalEndogenous levelAnimal study (in vivo)Other
In rats, methylmercaptoimidazole treatment significantly increased adrenal content of VIP and the other measured peptides.
In plain wordsIn rats, a thyroid-blocking drug raised the body's own VIP content in the adrenal gland.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseAdrenal VIP content after methylmercaptoimidazole
Study
ratn: not reported in source
Wistar rats, adrenal gland content by radioimmunoassay
Outcome group
Endogenous peptide levels · Endocrine and hormones
Source sentences
Summary
MMI treatment and Tx induced significant increase (p less than 0.05 or p less than 0.01) in these peptides.
2 context sentences(design, population, supporting numbers)
Summary · context
The thyroid hormone excess and deficient states were experimentally produced with thyroxine (T4) treatment for 2 weeks, methylmercaptoimidazole (MMI) for 4 weeks, or a thyroidectomized state (Tx) for 4 weeks.
Summary · context
7B2, NPY and VIP contents were measured by specific radioimmunoassays.
This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-0238050305
06AnimalEndogenous levelAnimal study (in vivo)Other
In rats, thyroidectomy significantly increased adrenal content of VIP and the other measured peptides.
In plain wordsIn rats, removal of the thyroid raised the body's own VIP content in the adrenal gland.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseAdrenal VIP content after thyroidectomy
Study
ratn: not reported in source
Wistar rats, adrenal gland content by radioimmunoassay
Outcome group
Endogenous peptide levels · Endocrine and hormones
Source sentences
Summary
MMI treatment and Tx induced significant increase (p less than 0.05 or p less than 0.01) in these peptides.
2 context sentences(design, population, supporting numbers)
Summary · context
The thyroid hormone excess and deficient states were experimentally produced with thyroxine (T4) treatment for 2 weeks, methylmercaptoimidazole (MMI) for 4 weeks, or a thyroidectomized state (Tx) for 4 weeks.
Summary · context
7B2, NPY and VIP contents were measured by specific radioimmunoassays.
This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-0238050306

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.